Results 151 to 160 of about 532,748 (308)

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Functional Cure for Hepatitis B Virus: Challenges and Achievements. [PDF]

Int J Mol Sci
Shechter O, Sausen DG, Dahari H, Vaillant A, Cotler SJ, Borenstein R.   +5 more
europepmc   +1 more source

Serial Epidemiological Studies of Hepatitis B Virus in a Village

, 1977
Kimio Fujita, Shigenobu Terashima, Fumio Tsuda, Mitsunobu Imai, Makoto Mayumi   +4 more
openalex   +2 more sources

Development and Initial Use of a New Inflammatory Bowel Disease Clinical Database Integrating Both Eastern and Western Clinical Characteristics

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Background The increasing incidence of inflammatory bowel disease (IBD) presents significant medical and societal challenges. A well‐designed IBD database is crucial for both epidemiological studies and clinical management. However, inconsistencies between regional databases hinder cross‐institutional and international research, especially ...
Jingshuang Yan, Rongrong Ren, Ruqi Chang, Wanyue Dan, Xiaohan Zhang, Fei Pan, Bin Yan, Hongzhe Lee, Ni Josie, Gang Sun, Lihua Peng, Gary D. Wu, Yunsheng Yang   +12 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Optimization of dried blood spot for hepatitis B virus surface antibody quantification. [PDF]

PLoS One
Motshosi P, Phinius BB, Jongman M, Baruti K, Bhebhe L, Mulenga G, Choga WT, Moyo S, Gaseitsiwe S, Anderson M.   +9 more
europepmc   +1 more source

Rearing and Management of Chimpanzees for Experimental Infection with Hepatitis B virus

, 1977
Kaoru KOSHIMIZU, Teruo Magaribuchi, Masahiro Ito, Koji Uchizono, Toshio Shikata   +4 more
openalex   +2 more sources

Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond

Cancer Communications, EarlyView.
Huiyao Huang, Huilei Miao, Jinling Tang, Ning Li   +3 more
wiley   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source